Neural systems that evolved to generate natural sleep are postulated to be preferentially involved in mediating anesthetically induced losses of waking consciousness. 2 Neurotransmitter-receptor systems known to be important for both sleep and anesthesia include glutamate and N-methyl-D-aspartate (NMDA) receptors 3,4 and acetylcholine (ACh) and muscarinic receptors. 5, 6 An interaction between these two neurotransmitter systems is the focus of the present report.
hours, after which the probe was removed from the brain stem and the craniotomy was closed. Repeated dialysis experiments in the same animal were separated by at least 1 week and the dialysis probe always was aimed for an unused site within the mPRF.
Microdialysis and high performance liquid chromatography (HPLC). As described elsewhere, 13, 17, 18 a series of ACh and choline (Ch) standards ranging from 0.2 to 3.0 pmol were injected into an HPLC system coupled to an electrochemical detector (Bioanalytical Systems Inc  (BAS), West Lafayette, IN). The resulting area of each chromatogram was used to create a standard curve for quantifying the pmol value of ACh obtained by in vivo brain microdialysis. The microdialysis probes had a 2-mm polycarbonate membrane and a molecular weight cut-off of 20KDa (Carnegie Medicin, Stockholm, Sweden). Probes were perfused at a continuous rate of 3.0 µl min -1 with Ringer's solution. Prior to stereotaxic placement of the probe in the pons, percent of ACh recovery by the probe was determined by dialyzing a solution containing a known concentration of ACh. After pontine placement of the probe, 30 µl dialysis samples were collected every 10 minutes throughout each experiment and injected immediately into the HPLC system. The samples were carried through the system at a flow rate of 1 ml min -1 . Acetylcholine and Ch were separated by an analytic column. A BAS immobilized enzyme reactor column converted ACh and Ch into proportional amounts of hydrogen peroxide, 19 which was measured using a dual platinum working electrode (500 mV applied potential) versus an Ag+/AgCl reference electrode. A chart recorder and a computer integration program (Chromgraph, © BAS) were used to evaluate, digitize, and quantify the resulting chromatograms. Acetylcholine levels were expressed as pmol/10 minutes of brain dialysis. At the conclusion of each experiment, when the probe was removed from the brain, ACh recovery by the probe again was quantified by dialyzing an ACh solution identical to the one used prior to probe placement in the brain. This procedure ensured that changes in ACh release within an experiment were not a result of damage to the dialysis probe membrane.
Data analysis. Respiratory rate (breaths/min) and percent time spent in states of REM sleep, NREM sleep, and wakefulness were calculated from a minute-by-minute analysis of the polygraph recordings. Each dialysis probe site was localized histologically within the mPRF by comparing cresyl violet-stained, sagittal sections of brain stem with a stereotaxic brain stem atlas. 15 The changes in ACh release and respiration were evaluated statistically with analysis of variance, t-test, and Figure 1 -Polygraphic and respiratory recordings during the natural sleep/wake cycle and during ketamine anesthesia. The four frames each show a one-minute recording from the same animal during wakefulness, NREM sleep, REM sleep, and following systemic administration of ketamine. The dissociated state of ketamine anesthesia was characterized by slow breathing (Resp), open eyes with an absence of movements (EOG), a mixed frequency cortical electroencephalogram (EEG) with spiking activity, a lack of ponto-geniculo-occipital (PGO) waves, and neck muscle hypotonia (EMG).
multiple comparison statistics.
RESULTS
Systemic ketamine produced a dissociated arousal state and decreased rate of breathing. Ketamine has been termed a dissociative anesthetic because it produces a state characterized by a dissociation between behavioral and electrographic variables. Behaviorally, animals that received ketamine were unresponsive to visual or tactile stimuli, while displaying open eyes with fixed gaze. Ketamine also enhanced salivary secretions. Electrographically, before receiving ketamine these animals exhibited normal sleep/wake cycles. Figure 1 shows that following systemic ketamine administration, the normal polygraphic signs of sleep were eliminated. Microdialysis measures of mPRF ACh ( Fig.  2A) following systemic administration of ketamine showed a decrease in ACh release (Fig. 2B) to levels less than measured during wakefulness (-12%), NREM sleep (-8%), and REM sleep (-49%). Rate of breathing (Fig. 2C ) slowed significantly following systemic ketamine administration.
Dialysis delivery of R(-)-ketamine into the mPRF decreased mPRF ACh release. Additional experiments sought to determine the effects of ketamine delivered into the mPRF on mPRF ACh release (Fig.  3A) . Commercially available ketamine is provided as a liquid, racemic (50:50) mixture of R(-)-and S(+)-enantiomers. This formulation is not suitable for administration via dialysis because it is not possible to make a solution of the appropriate molarity. Therefore, commercially available liquid ketamine could not be delivered directly into the mPRF. To overcome this limitation, the R(-)-enantiomer was dissolved in Ringer's to test the hypothesis that dialysis administration of R(-)-ketamine into the mPRF would decrease mPRF ACh release. Dialysis delivery of the R(-)-ketamine isomer into the mPRF significantly decreased ACh release within the mPRF (Fig. 3B ). Dialysis delivery of the R(-)-ketamine isomer did not alter breathing.
Dialysis delivery of MK-801 into the mPRF decreased mPRF ACh release and decreased the rate of breathing. MK-801 is a potent NMDA receptor antagonist that binds to the same site as ketamine within the NMDA receptor channel. Dialysis delivery of MK-801 into the mPRF significantly decreased mPRF ACh release within the first 30 minutes of drug administration ( Figure 4A ; min 110). Analysis of mPRF ACh release by dialysis condition (Fig. 4B) showed that MK-801 significantly decreased mPRF ACh release below Ringer's (control) levels. Figure 5A illustrates the time course of respiratory-rate depression caused by mPRF delivery of MK-801. These time-course data show a significant decrease in respiratory rate within the first 20 minutes of MK-801 administration. The average respiratory rate ( Fig. 5B ) was significantly decreased by mPRF dialysis delivery of MK-801. This respiratory-rate depression paralleled the decreased rate of breathing caused by systemic administration of racemic ketamine (Fig. 2C) .
DISCUSSION
For the three events necessary to activate NMDA receptors, 20 there are data consistent with the possibility that pontine NMDA receptors contribute to sleep-cycle control. First, NMDA receptor activation requires glutamate or aspartate to occupy an NMDA binding site. Excitatory amino-acid receptors are present in the pontine reticular formation, 21 and glutamate has been shown to modulate the motor atonia of REM sleep. 22 Second, glycine must bind as a co-agonist to a strychnineinsensitive site near the NMDA receptor. Unless glycine is present, the NMDA receptor can not be activated by glutamate. The cholinergic laterodorsal and pedunculopontine reticular nuclei (LDT/PPT) receive input from glycine-immunoreactive neurons 23 and both glycine and glutamate are present in the pontine reticular formation. 24 Third, another non-NMDA receptor must be activated to depolarize the neuronal membrane in which the NMDA receptor is localized. Some cells in the cholinergic LDT/PPT discharge before and throughout REM sleep, 25 providing ACh to the mPRF. 17 A. Sagittal schematic of cat brain illustrating placement of a microdialysis probe in the mPRF and cholinergic input to the mPRF from laterodorsal and pedunculopontine reticular nuclei (LDT/PPT). During systemic ketamine administration, the mPRF was dialyzed with Ringer's while measuring acetylcholine (ACh) release. B. ACh release in four animals during wakefulness (260 mins of dialysis), NREM sleep (220 mins of dialysis), and REM sleep (260 mins of dialysis) and following systemic administration of ketamine (120 mins of dialysis). Analysis of variance showed a statistically significant effect of arousal level on ACh release (p<0.001). Consistent with previous reports 13 , ACh release was significantly (* p<0.01) increased during REM sleep. C. Respiratory rate was analyzed for 799 breaths in four animals during wakefulness, NREM sleep, REM sleep and following systemically administered ketamine. Analysis of variance revealed a statistically significant arousal state main-effect on rate of breathing (* p<0.001). Respiratory rate following ketamine administration was significantly less than during wakefulness (p<0.001).
nificantly increased during REM sleep 13 and ACh depolarizes some mPRF neurons. 26 Enhanced discharge of LDT/PPT neurons during EEG-activated states of wakefulness and REM sleep has the potential to directly activate NMDA receptors because some LDT/PPT neurons also contain the NMDA receptor agonist glutamate. 27 Glutamate microinjected into rat PPT enhances cortical excitability. 28 Thus, there is a compelling body of evidence that pontine NMDA receptor mechanisms can alter physiologic traits characterizing arousal states.
NMDA receptors, ACh, and EEG activation. Pioneering studies of NMDA channel blockers on sleep in rat have reported an enhancement of EEG delta (1-4 Hz) power and 10 to 20 Hz power during REM sleep. 8, 29, 30 The present study did not perform EEG power spectral analyses, and states of sleep and wakefulness were scored using standard electrographic criteria for the cat. 14 As illustrated in Figure 1 , systemic administration of ketamine produced a dissociated arousal state 31 that could not be scored according to standard criteria. 14 The present data were obtained immediately following administration of ketamine or MK-801. In contrast, previous studies in rat noted that the EEG revealed a significant increase in EEG delta frequency 2 to 3 hours after systemic ketamine 4 or MK-801 infusion. 18, 29, 30 Thus, it is not possible to make quantitative comparisons of the present effects of ketamine in cat with existing sleep state data in rat. 8, 29, 30 Indirect comparisons, however, make clear that NMDA and cholinergic systems interact to modulate cortical and behavioral arousal. For example, ketamine anesthesia can be antagonized by acetylcholinesterase inhibitors, 12 and the acetylcholinesterase inhibitor neostigmine significantly enhances the EEG-activated state of REM sleep 32 and mPRF levels of ACh. 13 Inhibition of mPRF ACh release by the NMDA channel blockers ketamine and MK-801. The R(-)-isomer of ketamine was chosen for microdialysis delivery to the mPRF for two reasons. First, the R(-)-isomer is available in powder form, making it possible to dissolve in Ringer's solution and deliver via microdialysis. The second reason for studying R(-)-ketamine is that the R(-)-and S(+)-isomers of ketamine have different actions and different potencies. 33, 34 The R(-)-isomer of ketamine is believed to account for negative emergence reactions (e.g., disorientation and hallucinations) observed in 5% to 30% of patients receiving ketamine. 3, 35 Postoperative delirium remains poorly understood and clinically relevant. Postoperative delirium is associated with delayed recovery, increased time in the hospital, and increased morbidity. 36 The present results show for the first time that dialysis delivery of R(-)-ketamine significantly decreases ACh release in feline mPRF (Figure 3B) . The finding that dialysis delivery of MK-801 also decreased mPRF ACh release (Figure 4) is consistent with the interpretation that NMDA receptors in the mPRF modulate ACh release.
Inhibition of mPRF ACh release by R(-)-ketamine and MK-801 may be due to multiple mechanisms in addition to NMDA receptor blockade. Ketamine has many complex actions and interacts with multiple binding sites, including NMDA and non-NMDA receptors, nicotinic 37 and muscarinic receptors, monoaminergic receptors, and opioid receptors. 20 Postsynaptic muscarinic receptors contribute to sleep-cycle control, 38 and ketamine has been shown to inhibit muscarinic receptors. 33, 39 The foregoing data raise the question of whether the decreased ACh release caused by dialysis delivery of both ketamine (Fig. 3) and MK-801 (Fig.  4 ) might be due, in part, to actions on muscarinic receptors. Ketamine has an affinity for the NMDA receptor that is 10 to 20 times greater than for the muscarinic receptors. 40 This favors the interpretation that the decreased release of ACh in the mPRF arises in part from blockade of NMDA receptors on cholinergic terminals regulating ACh release in the mPRF. 17 Pontine glutamatergic and cholinergic neurotransmission alter the rate of breathing. The present results reveal significant respiratory-rate depression caused by racemic ketamine administered systemically (Figs. 1 and 2C ) and by dialysis delivery of MK-801 (Fig. 5) . Altered breathing during sleep and anesthesia is characterized by a disruption in respiratory-cycle timing. A failure to switch normally between the inspiratory and expiratory phases of the respiratory cycle can cause prolonged inspiration referred to as apneustic breathing. The pontine respiratory group is known to mediate a respiratory phase-switching or pneumotaxic function. 41 Many studies concur that pontine mechanisms regulating the transition from inspiration to expiration involve activation of NMDA receptors. 42 Respiratory-cycle timing is disrupted by microinjection of glutamate into the parabrachial pons of rat 43 and microinjection of MK-801 into the pontine respiratory group of cat. 44 In nonhuman primate, ketamine administration causes failure of normal pneumotaxic function, supporting the conclusion that NMDA receptors contribute to the normal termination of inspiration. 45 MK-801 disrupts sleep and depresses respiratory rate in ground squirrels, 46 and NMDA-receptor mechanisms contribute to medullary responses to hypoxia. 47 Two limitations of the present respiratory-rate data should be noted. First, although clinical data are clear that NMDA-channel blockers cause respiratory-rate depression, 3,48 the respiratory rate depression by ketamine (Fig. 2C ) and MK-801 (Fig. 5) may not be attributable solely to NMDA receptors. Cholinergic neurons in the LDT/PPT nuclei are adjacent to and co-mingle with cells comprising the pontine respiratory group. 49 R(-)-ketamine (Fig. 3) and MK-801 (Fig. 4) significantly decreased ACh levels in the pons, and pontine cholinergic transmission alters the excitability of pontine respiratory neurons. 50 As with the effects on ACh release, the ketamine and MK-801 effects on breathing may be due, in part, to alterations in multiple neurotransmitter systems, including ACh. The NMDA-channel blockers can even act on respiratory pump muscles. At the neuromuscular junction, glutamate and ACh are co-released, and both ketamine and MK-801 have been reported to suppress contraction of rat diaphragm. 51 present nasal-thermistor measures of respiratory rate do not permit accurate assessment of inspiratory (T I ) or expiratory (T E ) respiratory-cycle timing. Altered cholinergic neurotransmission in the pontine reticular formation, however, is known to significantly alter respiratory-cycle timing. 52, 53 In spite of these limitations, the results are consistent with a larger body of evidence showing that state-dependent changes in respiration can be evoked from regions of the mPRF that contain no respiratory neurons. 6 
